At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
Fingolimod +2 moredrug
Likely dose
Placebo (for Fish Oil) 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-α , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Fingolimod, Fish Oil, and 1 other intervention for Multiple Sclerosis. Completed, enrolled 50 participants.
Detailed Summary
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
Countries--
CollaboratorsShiraz University of Medical Sciences
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
Primary CompletionSep 2016
Study CompletionOct 2016
First PostedOct 2016
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartApr 1, 2015
Primary CompletionSep 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.7 years ago
Interventions
Fingolimoddrug
Produced by Osveh ® Pharm Company in Iran
Fish Oildietary
produced by Zahravi ® Pharm Company in Iran
Placebo (for Fish Oil)drug
placebo capsules to mimic Fish Oil 1 g capsules